Literature DB >> 29044880

Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.

Jonas Leichsenring1, Anna-Lena Volckmar1, Martina Kirchner1, Daniel Kazdal1, Mark Kriegsmann1, Fabian Stögbauer1, Teresa Bockmayr2, Frederick Klauschen2, Felix J F Herth3,4, Roland Penzel1, Arne Warth1,4, Peter Schirmacher1,5, Volker Endris1, Albrecht Stenzinger1,5.   

Abstract

During the course of disease, many cancer patients eventually present with metastatic disease including peritoneal or pleural spread. In this context, cytology specimens derived from ascites or pleural effusion may help to differentiate malignant from benign conditions and sometimes yield diagnosis of a malignancy. However, even when supported by immunohistochemistry, cytological interpretation can be challenging, especially if tumor cellularity is low. Here, we investigated whether targeted deep sequencing of formalin-fixed and paraffin embedded (FFPE) cytology specimens of cancer patients is feasible, and has diagnostic and clinical impact. To this end, a cohort of 20 matched pairs was compiled, each comprising a cytology sample (FFPE cell block) and at least one biopsy/surgical resection specimen serving as benchmark. In addition, 5 non-malignant effusions were sequenced serving as negative-controls. All samples yielded sufficient libraries and were successfully subjected to targeted sequencing employing a semiconductor based next-generation sequencing platform. Using gene panels of different size and composition, including the Oncomine Comprehensive Assay, for targeted sequencing, somatic mutations were detected in the tissue of all 20 cases. Of these, 15 (75%) harbored mutations that were also detected in the corresponding cytology samples. In four of these cases (20%), additional private mutations were detected in either cytology or tissue samples, reflecting spatiotemporal tumor evolution. Of the five remaining cases, three (15%) showed wild type alleles in cytology material whereas tumor tissue had mutations in interrogated genes. Two cases were discordant, showing different private mutations in the cytology and in the tissue sample, respectively. In summary, sequencing of cytology specimens (FFPE cell block) reflecting spatiotemporal tumor evolution is feasible and yields adjunct genetic information that may be exploitable for diagnostics and therapy.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29044880     DOI: 10.1002/gcc.22509

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Emerging Role of the Pathologist in Precision Medicine for HCC.

Authors:  Thomas Longerich; Peter Schirmacher
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 2.  Molecular Profiling of Malignant Pleural Effusions with Next Generation Sequencing (NGS): Evidence that Supports Its Role in Cancer Management.

Authors:  Georgia Ι Grigoriadou; Stepan M Esagian; Han Suk Ryu; Ilias P Nikas
Journal:  J Pers Med       Date:  2020-11-01

Review 3.  Molecular testing on serous effusion: An update.

Authors:  Saumya Sahu; Parikshaa Gupta; Pranab Dey
Journal:  Cytojournal       Date:  2021-12-06       Impact factor: 2.091

4.  RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.

Authors:  Martina Kirchner; Olaf Neumann; Anna-Lena Volckmar; Fabian Stögbauer; Michael Allgäuer; Daniel Kazdal; Jan Budczies; Eugen Rempel; Regine Brandt; Suranand Babu Talla; Moritz von Winterfeld; Jonas Leichsenring; Tilmann Bochtler; Alwin Krämer; Christoph Springfeld; Peter Schirmacher; Roland Penzel; Volker Endris; Albrecht Stenzinger
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

5.  Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.

Authors:  Célia Dupain; Julien Masliah-Planchon; Céline Gu; Elodie Girard; Pierre Gestraud; Pauline Du Rusquec; Edith Borcoman; Diana Bello; Francesco Ricci; Ségolène Hescot; Marie-Paule Sablin; Patricia Tresca; Alexandre de Moura; Delphine Loirat; Maxime Frelaut; Anne Vincent-Salomon; Charlotte Lecerf; Céline Callens; Samantha Antonio; Coralie Franck; Odette Mariani; Ivan Bièche; Maud Kamal; Christophe Le Tourneau; Vincent Servois
Journal:  Mol Oncol       Date:  2020-09-15       Impact factor: 6.603

6.  Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations.

Authors:  Go Eun Bae; Seok-Hwan Kim; Min Kyung Choi; Jin-Man Kim; Min-Kyung Yeo
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.